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Abstract
Glicentin is a proglucagon-derived peptide mainly produced in the L-intestinal cells. While the roles of other members of the proglucagon family 
including glucagon-like peptide 1, glucagon-like peptide 2 and oxyntomodulin has been well studied, the functions and variation of glicentin in 
human are not fully understood. Experimental and clinical studies have highlighted its role in both intestinal physiology and glucose metabolism, 
pointing to its potential interest in a wide range of pathological states including gastrointestinal and metabolic disorders. Due to its structure pre-
senting many similarities with the other proglucagon-derived peptides, its measurement is technically challenging. The recent commercialization of 
specific detection methods has offered new opportunities to go further in the understanding of glicentin physiology. Here we summarize the current 
knowledge on glicentin biogenesis and physiological roles. In the limelight of clinical studies investigating glicentin variation in human, we discuss 
future directions for potential applications in clinical practice.
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Gastrointestinal hormones correspond to a large 
family of various peptides released throughout 
the digestive tract including the stomach, the 
small intestine, the bowel as well as the pancreas 
(1-4). Thanks to their properties, these hormones 
play key roles in a wide range of physiological pro-
cesses including control of appetite, regulation of 
glucose and lipid metabolism, digestive motility, 
secretion or trophicity. Interestingly, some hor-
mones derive from larger precursors called pro-
hormones. Prohormones have minimal hormonal 
effects and usually represent an inactivated form 
of hormones, ready to be activated by post-trans-
lational modifications. 
Proglucagon is the archetype of a prohormone 
whose post-translational processing provides vari-
ous peptides with distinct and complementary bi-
ological functions. While the variations and roles 
of some members of the proglucagon family such 
as glucagon-like peptide 1 (GLP-1), glucagon-like 
peptide 2 (GLP-2) and oxyntomodulin are well 
documented, glicentin has been poorly investigat-
ed so far. Development of commercialized detec-
tion methods has recently offered new opportuni-
ties to get further in understanding the biology of 
this member of the proglucagon family. Here, we 
summarize the current knowledge on glicentin 
roles and pathophysiological variations. In the 
limelight of clinical studies, we discuss potential 
applications and future directions for clinical re-
search and medical practice. 
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Biogenesis of glicentin
Glicentin belongs to the proglucagon-derived 
peptides. The proglucagon gene is mainly ex-
pressed in the alpha-cells of the endocrine pancre-
as, as well as the intestinal L-cells (4,5). The pro-
glucagon gene is located on the chromosome 2 
and is composed of 6 exons and 5 introns (Figure 
1). The gene transcription leads to a messenger 
RNA (mRNA) which is translated into proglucagon, 
a 178 amino-acid precursor protein. While the 
structure of the proglucagon is identical in the 
pancreas and the intestine, its post-translational 
processing differs between these two organs, 
leading to various peptides, with distinct and com-
plementary biological functions. 
Schematically, the maturation in the pancreas in-
volves the proconvertase 2 and leads to four main 
products: the glicentin related pancreatic poly-
peptide (GRPP), the glucagon, the intervening 
peptide-1 (IP-1) and the major proglucagon frag-
ment (MPF) (4-8). In the enteroendocrine L-cells, 
post-translational processing of proglucagon, 
mainly mediated by proconvertases 1 and 3, liber-
ates the glicentin, the oxyntomodulin, the GLP-1, 
the intervening peptide-2 (IP-2) and the GLP-2 (4,6-
9). The mature form of glicentin is composed of 69 
amino acids and contains the entire sequences of 
glucagon and oxyntomodulin (10).
Figure 1. Processing of the proglucagon gene into proglucagon-derived peptides (modified from Baggio et al. (4), Holst et al. (5), Ba-
taille et al. (6, 7), Whiting et al. (8)) and DeFronzo et al. (47)).
(1) The proglucagon gene is located on the chromosome 2 and is composed of 6 exons and 5 introns. (2) The gene transcription leads 
to a messenger RNA. (3) The messenger RNA (mRNA) is translated into the proglucagon, a 178 amino-acid precursor protein. (4) Post-
translational processing in the alpha pancreatic cells involves mainly the proconvertase 2 (PC2) and leads to the glicentin related 
pancreatic polypeptide (GRPP), the glucagon, the intervening peptide-1 (IP-1) and the major proglucagon fragment (MPF). (5) An 
alternative pathway involving proconvertase 1 and 3 (PC1/3) can lead to glucagon like peptide 1 (GLP-1) formation in the pancreas. 
(6) In the enteroendocrine L-cells and in the central nervous system, post-translational processing of proglucagon is mediated by 
proconvertases 1 and 3 and liberates the glicentin, the oxyntomodulin, the glucagon like peptide 1, the Intervening Peptide-2 (IP-2) 
and the glucagon like peptide 2 (GLP-2). DNA - deoxyribonucleic acid.
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As the enteroendocrine L-cells are present from 
duodenum to rectum, glicentin can potentially be 
synthetized all along the digestive tract. Neverthe-
less, L-cells are rare before the terminal ileum and 
experiments in animal models revealed that tissue 
concentration of oxyntomodulin/glicentin were 
higher in distal ileum, caecum, and proximal colon 
compared to duodenum and proximal jejunum 
(11,12). These results suggest that the distal small 
bowel and the proximal colon are the main sites of 
the glicentin synthesis. 
Nevertheless, recent advances in the study of mo-
lecular mechanisms have unravelled previously 
unsuspected pathways. Indeed, several studies 
have highlighted that alpha pancreatic cells ex-
press proconvertase 1 and 3 and are able to pro-
duce and secrete GLP-1 (13,14). Further, an imma-
ture form of glicentin has been identified in the al-
pha cells (6). Interestingly, the proglucagon gene is 
also expressed by specific neurons in the central 
nervous system. Its post-translational processing is 
similar to the intestine and mature glicentin thus 
has been identified in the central nervous system 
(6). Hence, it is not excluded that future research 
on glicentin biogenesis could reveal new sites and 
pathways involved in its production. 
Glicentin and intestinal physiology
Experimental studies in several animal models in-
cluding piglets, dogs and rats have reported the 
role of glicentin in intestinal physiology (Table 1). 
First, glicentin secretion is stimulated by food in-
take as revealed by increased plasma glicentin 
concentrations after glucose, lipids and amino-ac-
ids loading into the duodenum (15-17). Several 
studies in rat model have highlighted the trophic 
role of glicentin on intestinal mucosa. Indeed, an 
increase of several parameters of mucosal growth, 
including weight, protein and DNA content, alka-
line phosphatase and ornithine decarboxylase ac-
tivities have been reported in the jejunum after 
glicentin subcutaneous injection (18). In vitro stud-
ies confirmed the proliferative action of glicentin 
on epithelial cell line IEC-6. Another study showed 
the trophic effect induced by glicentin in the small 
intestine, with a more pronounced effect in the il-
eum (19), whereas Myojo et al. did not observe any 
effect of glicentin in the ileum (18). These hetero-
geneous results could be, at least partly, explained 
by differences in the methodology used including 
rat feeding, glicentin concentration and adminis-
tration as well as markers used to assess intestinal 
proliferation. The authors further revealed a de-
Table 1. Summary of experimental studies on glicentin functions and variation





•	 Piglets - administration 
of butter, glycerol and 
sodium palmitate into 
the duodenum
Investigate the response 
of plasma glicentin to 
intraluminal fat loading.
•	 Increase of plasma glicentin following 
butter and palmitate administration
•	 Slight increase of plasma glicentin, 




•	 Piglets - administration 
of a mixture of 10 
amino acids into the 
duodenum
•	 Dogs - pancreatectomy, 
administration of 
arginine
Explore the effect of 
amino acids on glicentin 
secretion.
•	 Increase of plasma glicentin following 
amino acids administration
•	 Increase of total immunoreactive 
glucagon in pancreatectomized dogs 
following amino acids administration
Administration of amino acids enhances 
glicentin secretion from the gut.
Ohneda et 
al. (16)
•	 Piglets - administration 
of glucose into the 
duodenum
Investigate the 
secretion of glicentin in 
response to intraluminal 
administration of 
glucose.
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Effect of glicentin 
on intestinal 
trophicity
•	 Rats - subcutaneous 
injection of glicentin 
(50 µg/kg every 12h for 
2 weeks)
•	 In vitro - intestinal 
epithelial cell line 
IEC-6, incubation with 
glicentin (0–1000 ng/
mL) for 48h
Examine the trophic 
effects of glicentin 
on small-intestinal 
mucosa and on 
the small-intestinal 
epithelial cell line IEC-6
•	 Jejunum - increase of weight, 
protein, DNA content and alkaline 
phosphatase activity in animals who 
were injected with glicentin; increase 
of ornithine decarboxylase activity 
after intraperitoneal injection of 
glicentin
•	 Ileum - no difference between animals 
injected with glicentin and the control 
group
•	 In vitro - increase of tritium-thymidine 
incorporation and the number of IEC-6 
cells in presence of glicentin
Trophic effect of glicentin on intestinal 
mucosa.
Myojo et al. 
(18)
•	 Rats - parenteral 
nutrition for 6 days 
and administration 
of 1, 4, 20 or 80 µg/
rat of glicentin via the 
jugular vein
Examine the effects of 
glicentin on intestinal 
proliferation in vivo in 
the rat.
•	 Dose-dependent increase of mucosal 
proliferation in the small intestine 
induced by glicentin, with an effect 
more pronounced in the ileum
•	 Decreased crypt fission of the ileum 
in the 20 and 80 µg glicentin groups 
compared to controls
•	 No significant effect of glicentin on 
proliferation or fission in the colon
Trophic effect of glicentin on the small 
intestine but not on the colon.
Sasaki et al. 
(19)
•	 Rats - resection of 
the small intestine 
and aministration of 
methionyl rat glicentin 
(20 μ/day/rat) from 
the second day after 
the operation and 
during 28 days using 
miniosmotic pumps
Explore the effects of 
glicentin on intestinal 
adaptive responses to 
70% resection of small 
intestine in rats
•	 Rats with 70% distal intestinal 
resection - significant increase of the 
weight of the residual duodenum 
and its mucosal weight, protein, and 
diamine oxydase activity compared to 
controls. No significant change on the 
residual jejunum.
•	 Rats with 70% proximal intestinal 
resection - significant increase of the 
weight of the residual duodenum 
and its mucosal weight, protein, and 
diamine oxydase activity compared to 
controls
Stimulating activity of glicentin on the 




•	 Rats - construction 
of loops of jejunum 
and ileal Thiry-Vella 
fistulas (TVFs) that 
were isolated from 
the luminal stream 
and subcutaneous 
injection of glicentin 
(50 µg/kg every 12 
hours for 1 week)
Determine whether 
the trophic effect of 
glicentin is mediated by 
mechanism involving 
luminal or non-luminal 
factors and determine 
whether glicentin exerts 
a differential trophic 
effect on jejunal or ileal 
mucosa
•	 Effect of glicentin in the jejunal TVF 
group - increase of mucosal growth 
measurements in the TVF and the 
intact jejunum
Effects of glicentin on the proximal gut 
mucosa may be caused by a combination 
of non-luminal and luminal factors.
•	 Effect of glicentin in the ileal TVF 
group - stimulation of the proliferation 
of intact ileal mucosa but no effect on 
the ileal TVF
Effect on the ileal mucosa may be 
influenced by luminal contents and 
endogenous secretions.
Differential trophic effect of glicentin on 
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•	 Cell line, in vitro 
INT-407 cell lines - 
incubation of glicentin 
(100 ng/ml to 1 µg/ml) 
for 24h
•	 Assays on bacterial 
internalization with 
Salmonella enteritidis 
IFO 3313, Escherichia 
coli ATCC M44 and 
Enterococcus faecalis 
ATCC 29212
Determine the effect 
of recombinant human 
glicentin on bacterial 
internalization by 
confluent enterocytes
•	 Lower bacterial internalization 
through the glicentin-treated 
enterocytes than the non-treated
•	 Dose dependent effect of glicentin on 
bacterial internalization in the range 
from 500 to 1 µg/mL
Glicentin acts as a barrier-sustaining 
agent that inhibits extra-intestinal 
invasion of enteric bacteria and 
decreased bacterial translocation.
Chiba et al. 
(25)
•	 Human gastric 
biopsies - 7 cases with 
endoscopical intestinal 
metaplasia; 47 cases 
with no endoscopical 
intestinal metaplasia
•	 18 biopsies with 
histological intestinal 
metaplasia







glicentin expression in 
the gastric mucosa
•	 Detection of mRNA glicentin 
expression in 100% of cases with 
endoscopical intestinal metaplasia, in 
76,7% of cases with no endoscopical 
intestinal metaplasia
•	 Glicentin mRNA expression statistically 
associated with the existence of 
histological intestinal metaplasia and 








•	 Rats - glicentin IV 
infusion during the 5 
min preceding food 
onset and during the 
first 15 min of food 
intake
Investigate the effect 
of a systemic increase 
of glicentin on food 
intake, postprandial 
myoelectrical activity 
in duodenum, jejunum 
and ileum and the 
oro-caecal transit
•	 No effect of systemic injection of 
glicentin on food intake
•	 Reduction of duration of the 
postprandial myoelectrical activity on 




•	 Dogs - use of vagally 
denervated gastric 
pouches equipped 
with four strain gauge 
force transducers 
on the pouch, 
gastric body, antrum 
and duodenum. 
Injection of glicentin 
intra-veinously 
(1 nmol/kg)
Explore the effect 
of glucagon, GLP-1, 
GLP-2 and glicentin on 
gastroduodenal motility 
and their mechanisms 
of action
•	 Glicentin did not affect 
motilin-induced phase III contractions 
at any site
•	 Glucagon inhibited contractions in the 
pouch and the stomach
•	 GLP-1 inhibited contractions at all sites
•	 GLP-2 inhibited contractions in the 
pouch
Differential effect of proglucagon-related 
peptides on gastroduodenal motility.
Shibata et 
al. (48)
•	 Rabbit, in vitro - 
isolation of smooth 
muscle cells (SMCs) 
from rabbit antrum, 
incubation with 
glicentin (5 nmol/L)
Explore the effect 
of glicentin SMCs 
contraction isolated 
from the rabbit antrum
•	 Induction of SMCs contraction by 
glicentin
•	 Maximal contraction at 30 s
Rodier et al. 
(29)
•	 Rabbit, in vitro - 
isolation of SMCs 
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•	 Rabbit, in vitro - 
isolation of SMCs 





of the calcium/ 
phosphoinositide and 
the cyclic adenosine 
monophosphate (cAMP) 
pathways in rabbit 
antral SMCs
•	 Induction of SMCs contractions by 
glicentin
•	 Induction of a biphasic and rapid 
inositol (1,4,5)-trisphosphate (Ins(1,4,5)
P3) production by glicentin
•	 In the absence of extracellular 
calcium: glicentin induced Ins(1,4,5)P3 
production became monophasic
•	 Induction of a rapid increase of 
intracellular free calcium induced by 
glicentin
•	 Reduction of the cAMP content 
by glicentin of cells stimulated by 
forskolin
•	 Contractile effect of glicentin 
potentially mediated by stimulation of 
the phosphoinositide hydrolysis and 
inhibition of cAMP production
•	 Action of glicentin potentially 
mediated by receptor coupled to G 
proteins
Rodier et al. 
(28)
•	 Human, in vitro -  32 
preparations of human 
normal jejunal muscle 
strips
Investigate the enteric 
nervous responses to 
glicentin in the normal 
small bowel
•	 Inhibition of contraction reaction 
by glicentin after blockade of the 
adrenergic and cholinergic nerve
•	 Regulating inhibition of the 
contraction reaction in normal 
human jejunum via non-adrenergic 
non-cholinergic (NANC) nerves, and 
has a direct action on the jejunal 
muscle receptor.
Tomita et al. 
(27)
•	 Human, in vitro 
patients who 
underwent 
resections for colon 
adenocarcinoma (8 
right colons, 14 left 
colons); isolation of 
SMCs
•	 Rabbit - SMCs from 
antrum
Investigate the effect of 
glicentin on the motor 
activity of colon
•	 Human SMCs from colon - 
dose-related contraction of SMCs 
induced by glicentin. Decrease 
of contractile activity induced by 
glicentin when incubated with 
exendin-(9–39), a selective antagonist 
of GLP-1 receptor
•	 Rabbit SMCs from antrum - 
exendin-(9–39) dose dependently 
reduced the contractile activity of 
glicentin
Effect of glicentin in SMC contraction may 
be mediated by GLP-1 receptor.
Ayachi et al. 
(31)
Effect of glicentin 
on gastric acid 
secretion
•	 Rats - use of chronic 
gastric fistulas, 
stimulation of gastric 
acid secretion 
by pentagastrin, 
injection of glicentin 
intra-veinously (bolus 
3µg/kg, followed by 
600 ng/h or 120 ng/h)
Investigate the role of 
glicentin on gastric acid 
secretion
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Effect of glicentin 
on glucose 
metabolism
•	 Rats, in vitro - isolation 
of hepatocytes
Study the effect of 
glicentin on the glucose 
production and cAMP 
accumulation of 
isolated hepatocytes
•	 Glicentin and glucagon stimulated the 
release of glucose from hepatocytes 
into the medium
•	 Stimulation of cAMP production by 
glucagon and glicentin
•	 Degradation of glicentin into low 
molecular weight fragments during 
incubation with hepatocytes, with 
some fragments similar to glucagon
Thieden et 
al. (35)
•	 Dogs - use of in vivo 
local circulation in 
canine pancreas; 
administration of 
glicentin into the 
pancreaticoduodenal 
artery (400 ng for 10 
min)
Investigate the effect 
of glicentin-related 
peptides on the 
endocrine pancreatic 
function
•	 Plasmatic concentrations after glicentin 
(1-16) administration in the canine 
pancreas - decrease of glucagon
•	 Plasmatic concentrations after 
glicentin (62-69) administration in the 
canine pancreas - decrease of insulin 
and glucagon
Glicentin released during nutrient intake 
might inhibit the secretion of glucagon.
Ohneda et 
al. (36)
•	 Dogs - use of in vivo 
local circulation in 
canine pancreas; 
administration of 
glicentin into the 
pancreaticoduodenal 
artery (200 pmol for 
10 min)
Study the role of 
glicentin-related 
peptides on the 
endocrine pancreas
•	 Plasmatic concentrations after 
glicentin (1-16) and glicentin (62-69) 
administration in the canine pancreas 
- increase of insulin and decrease of 
glucagon
•	 Plasmatic concentrations after 
glicentin (62-69) administration in the 
canine pancreas - increase of insulin 
and decrease of glucagon
•	 Maximum response of insulin 
and glucagon within 20 min after 
glicentin (1-16) and glicentin (62-69) 




•	 Dogs - use of in vivo 
local circulation in 
canine pancreas; 
administration of 
glicentin into the 
pancreaticoduodenal 
artery (100 and 400 
pmol for 10 min)
Explore the effect of 
human recombinant 
glicentin on the 
endocrine function of 
the pancreas
•	 Plasmatic concentrations after glicentin 
administration at a dose of 100 pmol 
during glucose infusion - no significant 
change in blood glucose, slight 
increase of insulin, but not significant; 
no significant change of glucagon
•	 Plasmatic concentrations after glicentin 
administration at a dose of 400 pmol 
during glucose infusion - significant 
increase of blood glucose, significant 
increase of insulin, increase of glucagon
•	 Plasmatic concentrations after 
glicentin administration at a dose of 
100 pmol during arginine infusion - no 
significant change in blood glucose, 
significant increase of insulin, no 
significant change of glucagon
•	 Plasmatic concentrations after glicentin 
administration at a dose of 400 pmol 
during arginine infusion - no significant 
change in blood glucose, significant 
increase of insulin, increase of glucagon




GLP 1/2 - glucagon like peptide 1 and 2.
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crease of crypt fission in the ileum after glicentin 
administration (19). Crypt fission corresponds to 
the mechanism leading to new crypt formation 
and plays a major role in intestinal development. 
Increased crypt fission is observed following intes-
tinal damage or ulceration (20), after administra-
tion of chemical carcinogens in rats and in humans 
with precancerous defects (21,22). Even if further 
investigations are required for a better under-
standing of the physiological significance of de-
creased crypt fission, these results pinpoint the 
potential role of glicentin in intestinal mucosa re-
modelling. The observation that glicentin is in-
volved in mechanisms regulating mucosa devel-
opment and renewal, has led some investigators 
to explore the effect of glicentin on adaptive re-
sponse to intestinal resection (23). A significant in-
crease of the weight of the residual duodenum 
and its mucosal weight, protein, and diamine oxi-
dase activity was found in rats which underwent a 
70% distal intestinal resection and which received 
glicentin after the intervention compared to con-
trol animals. These results underline the trophic 
role of glicentin in intestinal post-surgery remod-
elling. To go further into the physiological mecha-
nisms, some authors aimed to determine whether 
the trophic effect of glicentin was mediated 
through pathways involving luminal or non-lumi-
nal factors (24). To achieve this goal, they used a 
model of rats with a construction of loops of jeju-
num and ileal fistulas that were isolated from the 
luminal stream. The authors found an increase of 
mucosal growth measurements in both the jejunal 
fistula and the intact jejunum, suggesting that the 
effect of glicentin on the proximal gut mucosa 
may be caused by a combination of non-luminal 
and luminal factors. In contrast, glicentin stimulat-
ed the proliferation of intact ileal mucosa but had 
no effect in the ileal fistula, meaning that the ef-
fect of glicentin on the ileal mucosa may be influ-
enced by luminal content and endogenous secre-
tions. Taken together, these results suggest a dif-
ferential trophic effect of glicentin on mucosa on 
the proximal jejunum and distal ileum. In addition 
to its trophic effect on intestinal mucosa, glicentin 
may also act as a barrier-sustaining agent. Indeed, 
the effect of recombinant human glicentin on bac-
terial internalization by confluent INT407 entero-
cytes cell lines using Salmonella enteritidis, Escheri-
chia coli and Enterococcus faecalis was determined 
(25). A lower bacterial internalization through the 
glicentin-treated enterocytes was observed com-
pared to the non-treated cells, revealing the inhib-
itory effect of glicentin on bacterial translocation 
and intestinal invasion. 
Intestinal motility represents a factor potentially 
influencing bacterial internalization. In vivo studies 
in animal models highlighted the effect of glicen-
tin on gut motility, as demonstrated by the reduc-
tion of the duration of the postprandial myoelec-
trical activity on duodenum and jejunum in rats 
infused by glicentin (26). Ex vivo studies using 
preparation of human normal jejunal muscle strips 
further revealed the inhibitory effect of glicentin 
on contraction reaction after blockade of the adr-
energic and cholinergic nerve (27). In contrast, 
studies on smooth muscle cells (SMCs) isolated 
from rabbit antrum revealed the stimulatory ac-
tion of glicentin on muscle contraction (28-30). 
This contractile effect of glicentin may be poten-
tially mediated by receptor coupled to G proteins 
and through the stimulation of the phosphoi-
nositide hydrolysis and cyclic adenosine 
monophosphate (cAMP) production (28). Further, 
a reduced contractile activity of glicentin was ob-
served after incubation with exendin-(9-39), a se-
lective antagonist of GLP-1 receptor, suggesting 
that glicentin action may be relayed, at least part-
ly, through GLP-1 receptor (31). Similarly to what 
was observed using SMCs from rabbit antrum, a 
dose-related contraction of SMCs isolated from 
human colon was found and this effect was inhib-
ited after incubation with exendin-(9-39) (31). Tak-
en together, these results reveal the stimulating 
role of glicentin on SMC contraction along the di-
gestive tract, an effect which may involve GLP-1 
receptor. At last, a study in rats revealed the inhibi-
tory effect of glicentin on gastric acid secretion 
(32). Based on its action on the stomach, some in-
vestigators aimed at exploring the role of glicentin 
in metaplasia and its relationship with Helicobacter 
pylori infection (33). Using human gastric biopsies, 
they revealed that glicentin mRNA expression was 
associated with the existence of histological intes-
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tinal metaplasia and positively correlated with Hel-
icobacter infection. Even if given its biological 
function, glicentin is of potential interest in the 
context of digestive oncology, these results should 
be interpreted with caution. In this study, mRNA 
glicentin expression was assessed, which means 
that the expression of the precursor proglucagon 
and not the mature glicentin form was analysed. 
Further investigations on glicentin protein expres-
sion would be required for a better understanding 
of its role and variation in context of intestinal 
metaplasia. To summarize, glicentin plays parac-
rine functions on the digestive tract through its in-
volvement in various processes including regula-
tion of intestinal trophicity and motility, as well as 
gastric acid secretion. Its potential implication in 
various pathophysiological conditions including 
cancers, infectious or inflammatory diseases re-
mains to be explored. 
Glicentin and glucose metabolism 
The family of proglucagon-derived peptides plays 
a major metabolic role through their involvement 
in glucose homeostasis. Glucagon is well known 
for its hyperglycemic action (6). On the opposite, 
main proglucagon-derived hormones produced 
in the intestine indirectly balance the effect of 
glucagon by exerting hypoglycemic actions. GLP-1 
stimulates insulin secretion, improves insulin sen-
sitivity and suppresses the release of glucagon 
(3,7). Oxyntomodulin has also a positive effect on 
insulin secretion (2,3). The role of GRPP in glucose 
metabolism has been less studied and is more 
controversial. Indeed, a few decades ago, Ohneda 
et al. observed an increase of plasma insulin con-
comitantly with a decrease of glucagon after GRPP 
administration into the pancreaticoduodenal ar-
tery in dogs, suggesting an incretin-like effect (34). 
However, a recent report revealed that GRPP in-
hibited glucose-stimulated insulin secretion from 
the isolated pancreas of adult male rats (8). The 
discrepancy between these two studies could be, 
at least partly, explained by differences in method-
ology used including species studied, GRPP syn-
thesis and administration or pancreas preparation. 
This underlines the real need of further research to 
fully understand the specific role of each member 
of the proglucagon family.  
In that context, glicentin effect was also investigat-
ed (Table 1). A first study found that glicentin stim-
ulated the release of glucose from rat hepatocytes, 
with a stimulation of cAMP production, an effect 
comparable to what observed after incubation 
with glucagon (35). The authors observed that 
during incubation with hepatocytes glicentin was 
degraded into low molecular weight fragments, 
some being very similar to glucagon, addressing 
the question whether glicentin could exert gluca-
gon-like effects through a possible degradation to 
glucagon. Nevertheless, these results should be 
interpreted with caution since this study was per-
formed 30 years ago and since then the sequence 
defining glicentin protein as well as the technolo-
gies to identify and purify it have largely evolved. 
In fact, several relatively more recent in vivo stud-
ies in dogs demonstrated that administration of 
glicentin led to an increase of plasma insulin and a 
decrease of glucagon (34,36,37). Hence, similarly 
to GLP-1 and oxyntomodulin, glicentin has an in-
sulinotropic action and exert an incretin-like ef-
fect. Even if the precise mechanisms involved in 
the insulin-releasing action of glicentin remains to 
be elucidated, these results pinpoint the potential 
interest of glicentin as marker and/or player of 
metabolic diseases such as diabetes or obesity. 
Circulating glicentin in humans
Given the role of glicentin in both intestinal physi-
ology and glucose metabolism, its potential inter-
est as non-invasive biomarker including digestive 
and metabolic diseases would be worth investi-
gating. Due to its structure, assessment of circulat-
ing glicentin concentration is challenging to ob-
tain a specific measurement which does not cross 
react with other proglucagon-derived peptides. 
Indeed, glicentin peptide contains the entire se-
quence of glucagon, GRPP and oxyntomodulin 
(Figure 1). This technical reason combined with the 
lack of commercialized methods to measure gli-
centin until recently contribute to explain why lit-
erature on circulating glicentin in human is poor 
and its variation not fully elucidated. 
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The first published reports investigated circulating 
glicentin concentration using a non-commercial-
ized radioimmunoassay associated with chroma-
tography (38) and a non-commercialized sand-
wich enzyme-linked immunosorbent assay (ELISA) 
(Table 2) (39-41). In the latest assay, the authors 
used two antibodies against the GRPP and the 
glucagon sequences and proved the specificity of 
the method to measure glicentin. Based on these 
studies, a solid phase two-site enzyme ELISA kit 
has recently been commercialized (Mercodia®, 
Uppsala, Sweden) and was used in several studies 
(42-44). The manufacturer tested the specificity of 
the assay and did not detect any cross reactivity 
with glucagon, oxyntomodulin, mini-glucagon, 
GLP-1 and GLP-2. At last, another commercialized 
ELISA kit has been developed (Merck-Millipore®, 
Billerica, United States) and was used in one study 











- Inter-assay variation: < 15%
- Intra-assay variation: < 10%
Plasma Patients who had acute pancreatitis(N = 83)
6.2 





- Detection limit: 3 pmol/L
- Inter-assay variation: < 
10.8%
- Intra-assay variation: < 8%
Plasma
 - Lean adolescents (N = 19)
 - Adolescents with obesity and 
normal glucose tolerance (N = 23)
 - Adolescents with obesity and im-
paired glucose tolerance (N = 19)
 - Adolescents with obesity and 
type 2 diabetes (N = 4)
17.6 (13 – 25)
23.6 (17.7 – 32.8)
18.2 (8.6 – 21.8)
15.1 (13.3 – 18)
- Manell et al. (42)
Serum
 - Lean adults (N = 52)
 - Adults with severe or morbid 
obesity (N = 39)
24 (18 - 38)
12 (7.6 – 17)
- Raffort et al. (44)
 - Adults with severe or morbid 
obesity before Roux-en-Y Gastric 
Bypass (RYGB) surgery (N = 18)
 - Adults 12 months after RYGB sur-
gery (N = 18)
 - Adults with severe or morbid 
obesity before Laparoscopic 
Sleeve Gastrectomy (LSG)† sur-
gery (n= 12)




19.7 ±  2.7
12.5 ±  1.4
16.4 ± 1.8




- Detection limit: 3.8 pmol/L
- Inter-assay variation: < 8%
- Intra-assay variation: < 5%
Plasma
 - Diabetic patients (N = 119)
 - Controls (N = 6) -
19.7 ± 2.1
18.6 ± 4.7
Naito et al. 
(39)
 - Very-low-birthweight infants (N 
= 21)
NV NV Shimizu et 
al. (41)





 - Non insulin-dependent diabetic 
patients (N = 8)
 - Controls (N =8)
NV NV Orskov et al. 
(38)
RYGB: Roux-en-Y Gastric Bypass. LSG: Laparoscopic Sleeve Gastrectomy. NV - no exact values.
Table 2. Methodology used to measure fasting circulating glicentin concentrations in human
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(45). The different ELISA tests share similarities, 
with detection limit for human glicentin close to 3 
pmol/L, inter-assay variation less than 15% and in-
tra-assay variation less than 10% (Table 2), allow-
ing the comparison of results among different 
studies. However, data regarding pre-analytical 
conditions are to date extremely poor. According 
to results provided by manufacturers, higher gli-
centin concentrations were obtained when using 
dipeptidyl peptidase-4 inhibitor while protease 
and esterase inhibitors did not seem to have an ef-
fect on glicentin stability. Hence, when comparing 
results among different studies, it should be taken 
into consideration that methodology used for 
sample collection and preservation could have po-
tentially impacted on glicentin concentrations.
The studies published so far confirmed the stimu-
lating effect of glucose ingestion on glicentin se-
cretion, as demonstrated by higher glicentin con-
centration after oral glucose tolerance test (OGTT) 
compared to fasting concentrations (38,39,42) (Ta-
ble 3). Besides, similarly to what was observed in 
animal models, food intake stimulates glicentin se-
cretion, as revealed by higher glicentin concentra-
tions after feeding in children (40,41). As animal 
models demonstrated the role of glicentin in intes-
tinal mucosa growth and trophicity, some authors 
investigated its variation in children from birth to 
Table 3. Summary of studies on circulating glicentin variation in human
Population Aim Glicentin detection method Main results References
- 83 patients who had 
acute pancreatitis: 30 
developed abnormal 
glucose metabolism, 






to be produced 
in both gut and 








- Significant decrease in glicentin, 
oxyntomodulin, vasoactive intestinal 
peptide (VIP) in individuals with abnormal 
glucose metabolism




- 52 lean adults






obesity and study 







- Significant decrease of glicentin 
concentration in patients with severe or 
morbid obesity compared to lean subjects
- No linear correlation between glicentin 
concentration and body mass index, 
glycaemic parameters (glycaemia, 
insulinemia, C-peptide) or lipid parameters 
(total, HDL, LDL-cholesterol, triglyceride)
Raffort et al. 
(44)
- 30 adult patients with 
severe or morbid obesity, 
eligible to bariatric 
surgery: 18 patients had a 
Roux-en-Y Gastric Bypass 
(RYGB), 12 patients had 
a Laparoscopic Sleeve 
Gastrectomy (LSG), 













- Significant increase of glicentin at 6 months 
post-surgery, with an effect more marked at 
12 months
- Tendency to have a more marked increase 
of glicentin after RYGB compared to LSG
- Significant increase of glicentin/ glycaemia, 
glicentin/insulinemia, glicentin/C-peptide 
ratios after surgery
- Improvement of metabolic parameters 
(anthropometric, glycaemic and lipidic) after 
surgery
- No direct correlation between glicentin 
variation and metabolic parameters variation
Raffort et al. 
(43)
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- 19 lean adolescents
- 23 obese adolescents with 
normal glucose tolerance 
(NGT)
- 19 obese adolescents with 
impaired glucose tolerance 
(IGT)
- 4 obese adolescents with 
















 - No significant difference on fasting glicentin 
concentrations between lean adolescents and 
adolescents with obesity and NGT. 
- Lower fasting glicentin concentrations in 
adolescents with obesity and IGT compared to 
adolescents with obesity and NGT
- Glicentin concentrations after oral glucose 
tolerance test (OGTT): lower in adolescents 
with obesity and IGT than those with NGT; 
peak at 30 minutes in lean adolescents and 
adolescents with obesity and NGT; peak at 
15 minutes in adolescents with obesity and 
IGT;peak at 60 minutes in adolescents with 
obesity and T2D
- Ratios of glicentin/glucagon and GLP-1/ 
glucagon: in fasting: lower ratios in obese 
adolescents with IGT and T2D than obese 
adolescents with NGT; during OGTT: lower 
ratios in obese adolescents with NGT than 
lean adolescents and lower ratios in obese 
adolescents with IGT and T2D than obese 
adolescents with NGT
- Fasting plasma glicentin as a predictor of 
IGT in adolescents with obesity and normal 
fasting glucose: 100% sensitivity and 56% 
specificity 
Manell et al. 
(42)
- 21 very-low-birthweight 
infants: 11 infants had early 
feeding with breast milk 
within 24h after birth, 10 
infants had breast milk 
more than 24h after birth
Explore the 
effects of early 
enteral feedings 
and the secretion 








- Glicentin basal concentration: early feeding 
group: higher glicentin concentrations 
at day 5-6 and day 14 after birth than at 
day 1 – 2; control group: higher glicentin 
concentrations at day 14 after birth than at 
day 1 – 2; higher glicentin concentrations 
in the early feeding group compared to 
controls at day 5 - 6 and day 14 after birth
- Post prandial glicentin concentration: 
early feeding group: higher glicentin 
concentrations after feeding than before 
feeding at day 5 - 6 and day 14; control 
group: higher glicentin concentrations after 
feeding than before feeding at day 14
Shimizu et 
al. (41)
- 119 developing children: 
21 children aged 15 to 29 
days, 16 children aged 1 
to 5 months, 14 children 
aged 6 to 11 months, 16 
children aged 1 to 3 years, 
17 children aged 4 to 7 
years, 18 children aged 8 to 
11 years, 17 children aged 
12 to 15 years 
- Term and preterm 
infants: 11 term and 
normal birthweight, 
9 low birthweight, 10 
very-low-birthweight
- Normal birthweight 
children:14 breastfed and 
11 formula-fed
Investigate 
the changes in 
basal plasma 
concentrations 
of glicentin in 







- Glicentin basal concentration: higher 
glicentin concentrations in children aged 
15 to 29 days, 1 to 5 months versus children 
aged 1 to 3 years, 4 to 7 years, 8 to 11 years; 
higher glicentin concentrations in children 
aged 6 to 11 months versus children 
aged 1 to 3 years, 8 to 11 years, 12 to 15 
years; higher glicentin concentrations in 
very-low-birthweight children versus normal 
birthweight children at day 1 or 2 after birth
- Post prandial glicentin concentration: 
higher glicentin concentrations after feeding 
than before at 1 - 2 days after birth and 
5 - 6 days in normal and low-birth-weight 
children; higher glicentin concentrations 
after feeding than before at 14 days after 
birth in very low-birth-weight children; 
no significant difference in glicentin 
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- 6 normal subjects
- 119 diabetic patients
- 15 gastrectomized 
patients - 9 with subtotal 
gastrectomy, 6 with 
total gastrectomy, 1 with 












- Fasting glicentin concentration: no 
significant difference on plasma glicentin 
concentrations between normal subjects 
and diabetics; no correlation between 
glicentin concentrations and plasma glucose
- Glicentin concentration after OGTT: 
increase of plasma glicentin in normal 
subjects; higher peak of glicentin at 30 min 
in gastrectomized patients compared to 
normal subjects; no significant variation of 
glicentin in the patient who had a massive 
small bowel resection
Naito et al. 
(39)
- 8 noninsulin-dependent 
diabetics (T2D)
- 8 weight-matched 
non-diabetic controls
Identify stimuli 













- Fasting glicentin: mean amount of total 
glucagon immunoreactivity eluting at 0.3 
Kd (corresponding to the elution of porcine 
glicentin), lower in T2D than controls
- Glicentin after OGTT: increase of glicentin 
secretion; mean amount of total glucagon 
immunoreactivity eluting at 0.3 Kd 
(corresponding to the elution of porcine 




VIP - vasoactive intestinal peptide. HDL - high-density lipoprotein. LDL - low-density lipoprotein. RYGB - Roux-en-Y gastric bypass. 
LSG - laparoscopic sleeve gastrectomy. NGT - normal glucose tolerance. IGT - impaired glucose tolerance. T2D - type 2 diabetes. 
GLP-1 - glucagon like peptide 1. OGTT - oral glucose tolerance test.
15 years’ age and revealed significant variations 
depending on children age (40). Interestingly, dif-
ferences on fasting glicentin concentrations were 
observed between children with very low-birth-
weight and normal birth weight children, suggest-
ing that glicentin could play a role in gastrointesti-
nal function and growth in the early period of life. 
In addition, feeding in children may shape and im-
pact on glicentin secretion. Early enteral feeding 
within 24 hours after birth in very low birth weight 
children led to higher glicentin basal concentra-
tion at day 5–6 and day 14 after birth compared to 
infants fed more than 24 hours after birth (41). Be-
sides, even if no significant difference in post-
prandial glicentin concentrations was observed 
between breastfed and formula-fed children in 
this study, the potential impact of the nature of 
food ingested on glicentin secretion cannot totally 
be excluded.  
In addition to its role in intestinal physiology, ex-
perimental studies have highlighted the effect of 
glicentin on glucose metabolism. Some authors 
addressed its variation in the context of diabetes. 
While a first study measured fasting glicentin con-
centration using a non-commercialized radioim-
munoassay combined with chromatography re-
vealed lower glicentin concentrations in type 2 di-
abetic patients compared to controls (38), others 
investigators did not find any significant difference 
using a non-commercialized sandwich ELISA in a 
larger cohort of patients (39). However, the authors 
found high glicentin concentrations in a diabetic 
patient with renal failure suggesting that glicentin 
may be excreted through the kidney (39). Given 
the development of new commercialized method 
which may improve reproducibility of circulating 
glicentin measurement, it would be worth investi-
gating its variation in large cohorts of patients and 
different types of diabetes to evaluate its potential 
usefulness as non-invasive biomarker of the dis-
ease. 
A recent study aimed at exploring glicentin varia-
tion in obese adolescents who had associated 
metabolic disorders (42). While no significant dif-
ference on fasting glicentin concentrations were 
observed between lean adolescents and adoles-
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cents with obesity and normal glucose tolerance 
(NGT), adolescents with obesity and impaired glu-
cose tolerance (IGT) had significantly lower glicen-
tin concentration at fasting state and after OGTT 
compared to those with obesity and NGT (42). Be-
sides, the profile of glicentin secretion observed 
after OGTT differs between diabetic and healthy 
subjects and between obese adolescents with 
NGT, IGT or type 2 diabetes (38,42). These results 
suggest that glicentin concentrations may be in-
fluenced by metabolic disorders and altered glu-
cose homeostasis rather than by the weight or the 
body mass index itself. This hypothesis is corrobo-
rated by the fact that no correlation was observed 
between body mass index and glicentin concen-
trations (44,45). In addition, decreased fasting gli-
centin concentrations was observed in patients 
with abnormal glucose metabolism after acute 
pancreatitis, confirming the link between glicentin 
concentration and defective glucose homeostasis 
(45). Nevertheless, the impact of glucose homeo-
stasis on glicentin secretion may results from com-
plex mechanisms which are not fully elucidated. 
Even if glucose intake stimulates glicentin secre-
tion, no linear correlation was found between fast-
ing glicentin and plasma glucose (39,44). Besides, 
in obese adolescents with IGT and type 2 diabetes, 
ratios of glicentin/glucagon and GLP-1/glucagon 
at fasting and after OGTT were lower compared to 
obese adolescents with NGT. This means that im-
paired glucose homeostasis may favour the pro-
duction of pancreatically cleaved proglucagon-
derived peptides (glucagon) at the expense of in-
testinally cleaved peptides including glicentin and 
GLP-1 (42). At last, the authors investigated if gli-
centin could have a predictive value of IGT in 
obese adolescents with normal fasting glucose 
and found that fasting glicentin measurement had 
sensitivity at 100% and specificity at 56% at a cut-
off of 22.05 pmol/L, lower concentrations indicat-
ing IGT (42). Even if further studies are required, 
glicentin could potentially represent a biomarker 
of obesity-related metabolic disorders. 
Interestingly, obese patients had lower fasting gli-
centin concentrations compared to control lean 
subjects at baseline (44). Moreover, a significant in-
crease of glicentin was observed in obese patients 
who underwent bariatric surgery at 6 and 12 
months’ post-intervention (43). Patients receiving 
a Roux-en-Y gastric bypass (RYGB), which consists 
in reducing the size of the stomach to a small 
pouch and shunting the duodenum and the proxi-
mal jejunum were compared to patients submit-
ted to a laparoscopic sleeve gastrectomy (LSG), 
consisting in a longitudinal resection of the stom-
ach. LSG is a restrictive procedure whereas RYGB 
associates restrictive and malabsorptive effects. 
The increase of glicentin post-surgery tended to 
be more marked after RYGB compared to LSG. 
Hence, bariatric surgery appears to restore, at least 
partly, glicentin secretion. The impact of digestive 
surgery on glicentin secretion has been so far 
poorly investigated. One study reports a higher re-
sponse of glicentin secretion after OGTT in pa-
tients who had a gastrectomy compared to con-
trols whereas no significant response was found in 
a patient who underwent a massive small bowel 
resection (39). Taken together, these results cor-
roborate the findings in animal models that the 
distal small bowel may be a major site of glicentin 
production (12). In addition, enhanced glicentin 
secretion after surgery may result from early stim-
ulation of the distal gut mucosa by nutrients as a 
result of rapid gastric emptying. At last, bariatric 
surgery has proven its efficiency to improve obesi-
ty-related metabolic disorders (46). As glicentin 
plays a role in glucose homeostasis and reversely 
metabolic disorders impact on its secretion, fur-
ther studies are required to determine whether it 
could be an actor and/or a marker of metabolic 
improvement observed after bariatric surgery. 
Conclusion and future directions
Glicentin has been much less studied than other 
proglucagon-derived peptides such as GLP-1, GLP-
2 or oxyntomodulin. This may be, at least partly, 
explained by the lack of commercialized detection 
methods available until recently. Glicentin is pro-
duced by L-intestinal cells from the duodenum to 
the rectum, with a main secretion probably locat-
ed in the distal small bowel and the proximal co-
lon. Its secretion is stimulated by food intake and 
experimental studies highlighted its role in intesti-
nal growth, trophicity and motility. In addition to 
its paracrine function on the digestive tract, gli-
Biochemia Medica 2017;27(2): 308–24  https://doi.org/10.11613/BM.2017.034 
322
Raffort J. et al. Insights on glicentin
centin plays a role in metabolism, mainly in glu-
cose homeostasis regulation through exerting in-
cretin-like effects. The implication of glicentin in 
both intestinal physiology and glucose homeosta-
sis points to various potential applications. Recent 
advances to assess its circulating variations in hu-
man offers promising perspectives to investigate 
its usefulness as non-invasive biomarker of various 
pathological states including intestinal diseases 
such as inflammatory pathologies or colorectal 
cancers, as well as metabolic disorders like diabe-
tes or obesity. In parallel, advances in fundamental 
research on proglucagon-derived peptides bio-
genesis could provide new pathways involved in 
glicentin production and secretion and would be 
useful for a better understanding of its action and 
its link with other proglucagon-derived peptides. 
Despite its discovery a few decades ago, the field 
is still in its infancy and we truly believe that new 
technologies and further experimental and clinical 
studies could bring innovative perspectives to use 
glicentin as a biomarker and/or as a potential ther-
apeutic target of several pathological states. 
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